Contents 2 min read

Claim and source comparison

Comparison limited to the intravenous NALT pharmacokinetic abstract, an L-tyrosine narrative-review abstract and two drug labels. These sources do not establish oral NALT cognitive efficacy, dose conversion or personal-use safety.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human pharmacokinetic study

Magnusson et al. (1989) studied 5 g of NALT or N-acetyl-L-cysteine as four-hour intravenous infusions in 11 healthy volunteers. Within four hours, 56% of the administered NALT amount was excreted unchanged in urine.

This is an intravenous metabolism experiment, not an oral-absorption, cognitive-outcome or clinical-superiority trial against L-tyrosine. A 56% urinary recovery cannot yield 44% oral bioavailability; a four-hour collection is not a half-life.

Source 4 · Abstract read

Narrative review

The Jongkees et al. (2015) review concerns L-tyrosine supplementation. The abstract read does not establish oral NALT cognitive superiority, faster effects or use at the same dose as L-tyrosine.

A parent-compound experiment cannot automatically establish clinical efficacy of its acetylated derivative. This limited reading does not claim all NALT research is absent; distinguish a research question from a demonstrated result.

Source 3 · Abstract read

Official safety summary

The phenelzine label contraindicates L-tyrosine but does not separately name NALT. The levodopa label describes absorption competition with certain amino acids, not NALT-specific clinical interaction magnitude. Neither establishes that NALT is safe with medication.

Medication users should review NALT with a doctor or pharmacist. Do not change prescribed medication. Absence of a separate name in a label is not safety evidence; these sources also do not establish pregnancy/breastfeeding or long-term safety.

Source 5 · Source 6 · Official summary read

Our evidence and source methodology

N-Acetyl L-Tyrosine: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is N-Acetyl L-Tyrosine?

NALT is acetylated L-tyrosine. Findings on cognition under stress largely concern free L-tyrosine; the same efficacy, dose or onset has not been established for NALT.

Clinical Evidence

Magnusson et al. (1989) studied 5 g of NALT or N-acetyl-L-cysteine as four-hour intravenous infusions in 11 healthy volunteers. Within four hours, 56% of the administered NALT amount was excreted unchanged in urine.

This is an intravenous metabolism experiment, not an oral-absorption, cognitive-outcome or clinical-superiority trial against L-tyrosine. A 56% urinary recovery cannot yield 44% oral bioavailability; a four-hour collection is not a half-life.

The Jongkees et al. (2015) review concerns L-tyrosine supplementation. The abstract read does not establish oral NALT cognitive superiority, faster effects or use at the same dose as L-tyrosine.

A parent-compound experiment cannot automatically establish clinical efficacy of its acetylated derivative. This limited reading does not claim all NALT research is absent; distinguish a research question from a demonstrated result.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

The phenelzine label contraindicates L-tyrosine but does not separately name NALT. The levodopa label describes absorption competition with certain amino acids, not NALT-specific clinical interaction magnitude. Neither establishes that NALT is safe with medication.

Medication users should review NALT with a doctor or pharmacist. Do not change prescribed medication. Absence of a separate name in a label is not safety evidence; these sources also do not establish pregnancy/breastfeeding or long-term safety.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Neri DF, et al. (1995). The effects of tyrosine on cognitive performance during extended wakefulness. Aviation, Space, and Environmental Medicine, 66(4), 313–319. PubMed · PMID 7794222
  2. Mahoney CR, et al. (2007). Tyrosine supplementation mitigates working memory decrements during cold exposure. Physiology & Behavior, 92(4), 575–582. PubMed · PMID 17585971
  3. Jongkees BJ, et al. (2015). Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands-A review. Journal of Psychiatric Research, 70, 50–57. PubMed · PMID 26424423
  4. Magnusson I, et al. (1989). N-acetyl-L-tyrosine and N-acetyl-L-cysteine as tyrosine and cysteine precursors during intravenous infusion in humans. Metabolism, 38(10), 957–61. https://doi.org/10.1016/0026-0495(89)90005-x PubMed · PMID 2507878
  5. DailyMed. Phenelzine sulfate: US prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa041652-fdde-4794-a8d2-279dd309e075 DailyMed / US National Library of Medicine
  6. DailyMed. Carbidopa and levodopa: US prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f6d393e-ac84-4a3c-a837-199d1ec71fd2 DailyMed / US National Library of Medicine

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions